Phase 4 N=353,323 Mupirocin-Iodophor ICU Decolonization Swap Out Trial
Staphylococcus Aureus
Primary: Number of Participants With ICU-attributable Staphylococcus Aureus Clinical Cultures — 2708; 3563 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Prostate Cancer
Primary: Time to Disease Progression — 15.2 weeks
Phase 2 N=54 S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Colon Adenocarcinoma · ERBB2 Gene Amplification · Rectal Adenocarcinoma
Primary: Progression-free Survival(PFS) — 4.7; 3.7 Months — p=0.44
Phase 2 N=38 RZL-012 for Dercum's Disease Lipomas
Dercum's Disease Lipomas
Primary: Efficacy - Change in Lipomas Dimensions — -15.13; -15.92 percentage of change from baseline
N/A N=12 Online Diabetes Education Project (ODEP)
Diabetes Mellitus, Type 2
Primary: Metabolic Control of A1c (Mean Change in A1C) — -0.02 percent
Phase 3 N=614 Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
Dengue Fever
Primary: Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58 — 1633.693; 1790.986; 1342.745; 1325.192 titer
N/A N=11 Feasibility of Unattended Home Polysomnography and Comparison to In-laboratory Polysomnography in Pediatric Patients
Sleep Apnea, Obstructive
Primary: Greater Than or Equal to 6 Hours of Sleep Data — 1 Participants
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Phase 4 N=25 Profiling the Skin Microbiome in Response to Altreno in Acne Patients
Acne · Healthy
Primary: CLR-transformed Abundance of Any Significant Taxa — 3.29; -2.49; -1.59; -2.75 Relative Abundance
Phase 4 N=701 Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
Migraine · Migraine Disorders · Migraine Headache
Primary: Exposure Adjusted Incidence Rate of AE During Open-label Treatment Epoch Per 100 Subject Years — 101.71 number of AEs per 100 patient-years
N/A N=993 Bangladesh PRODUCTIVity in Eyecare Trial
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Number of Completed Care Encounters Among Clinic Patients With Diabetes Per Retina Specialist Clinic Hour — 1.59; 1.14 care encounters/specialist clinic hour
N/A N=18 Impacts of a Combined Berry Extract Supplement on Vascular Function and Oxygen Utility Capacity in Young Adults
Healthy
Primary: Endothelial Function — 11.7; 8.2 percent dilation
Phase 2 N=14 A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
Advanced Malignancies
Primary: Number of Patients With Adverse Events or Serious Adverse Events — 0; 1; 1; 1 Participants
Phase 2 N=102 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
Ductal Breast Carcinoma In Situ · Invasive Breast Carcinoma · Stage 0 Breast Cancer
Primary: Percentages of Participants by EORTC Breast Cosmetic Rating Score at 24 Months Post-radiation Therapy — 17; 26; 24; 11 Participants
Phase 3 N=543 A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Locally Advanced or Metastatic and Unresectable HCC
Primary: Overall Survival (OS) — 22.1; 15.2 months